Agranulocytosis and profound neutropenia in the neonatal period is a serious condition associated with high mortality. Most patients develop fever associated with skin infections, pneumonia or septicaemia, or both, within the first days of life. The infections are predominantly caused by Staphylococcus aureus, and less often by Escherichia coli or haemolytic streptococci. Prophylaxis with antibiotics has been recommended for these infants.'
A boy with neonatal The response to intravenous immunoglobulin in immune thrombocytopenia is most favourable in the acute form of the disorder. In chronic disease the results parallel those in our case-a prompt rise but one which only lasts for two to three weeks.
In this boy, immunoglobulin infusion resulted in a temporary return to normal of the granulocyte count over a time period corresponding to the expected half life for IgG of three weeks. This agrees with a recent report on immunoglobulin treatment for an immune neutropenia in older children.4 High dose immunoglobulin treatment seems to be a safe and easy method of curing, at least temporarily, immune neutropenia, and covering a critical period of high risk for serious infectious complications. It should bear substantially fewer complications than plasma exchange. Intravenous immunoglobulin treatment is not, however, indicated in other forms of neutropenia, and should not be given to a newborn or any other child who just happens to be neutropenic. 
agranulocytosis.
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